Education
About Us
Working with TipRanks
Follow Us
Kymera Therapeutics (KYMR)
NASDAQ:KYMR
Top Page
Kymera Therapeutics
(NASDAQ:KYMR)
48Neutral
Positive Factors
Drug Development
KYMR is the front-runner among the increasingly competitive and strategically attractive landscape of STAT6 targeting therapies.
Intellectual Property
KYMR seems to have covered their ground thoroughly with thousands of pages across the patents, underscoring their lead position in development of a STAT6 degrader.
Negative Factors
Risk Assessment
Analyst's recommendation is cautious on the risk/benefit profiles of lead assets given the high bar for success.
Kymera Therapeutics (KYMR) vs. S&P 500 (SPY)
Market Cap
$2.16B
Dividend YieldN/A
Average Volume (3M)626.45K
Price to Earnings (P/E)―
Beta (1Y)2.41
Revenue Growth-40.11%
EPS Growth-17.79%
CountryUS
Employees187
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.97
Shares Outstanding64,944,140
10 Day Avg. Volume955,806
30 Day Avg. Volume626,452
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)45.90
Price to Cash Flow (P/CF)-8.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$58.83Price Target Upside67.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Kymera Therapeutics Business Overview & Revenue Model
Company DescriptionKymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
How the Company Makes MoneyKymera Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments, and potential royalties on sales of products developed using their technology. Additionally, the company may also receive funding through research grants and government contracts to support the development of their therapeutic candidates. As Kymera advances its own pipeline of drug candidates, the commercialization of approved therapies would also become a significant source of revenue.
Kymera Therapeutics Financial Statement Overview
Summary
Kymera Therapeutics shows typical characteristics of a biotechnology firm in a growth phase, with declining revenue and high R&D costs leading to net losses. A strong equity base and low leverage are positives. However, cash flow management remains a challenge.Income Statement
Kymera Therapeutics has experienced declining revenue over the past year, with a notable drop of 40.1% from $78.59M to $47.07M. The company operates at a loss, as indicated by negative EBIT and net income, leading to negative margins. The gross profit margin remains high due to the absence of cost of goods sold, but the net profit margin is significantly negative, reflecting the company's high operating costs relative to its revenue.45
Neutral
Balance Sheet
The balance sheet shows strong equity relative to liabilities, with a debt-to-equity ratio of 0.10, indicating low leverage. However, the company's return on equity is negative due to its net losses. The equity ratio is healthy at 85.4%, suggesting stability in its asset financing structure, primarily through equity rather than debt.65
Positive
Cash Flow
Operating cash flow is negative, reflecting cash outflow from operations. However, the company has managed free cash flow deficit through substantial financing activities. There is a significant increase in free cash flow deficit from the previous period, indicating potential cash management challenges.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 47.07M | 78.59M | 46.83M | 72.83M | 34.03M | Gross Profit |
| 47.07M | -110.49M | 43.85M | 70.44M | -28.07M | EBIT |
| -261.63M | -165.53M | -161.26M | -100.53M | -46.30M | EBITDA |
| -216.24M | -143.20M | -151.66M | -97.64M | -43.72M | Net Income Common Stockholders |
| -223.86M | -146.96M | -151.83M | -98.00M | -43.95M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 488.74M | 374.88M | 559.49M | 567.61M | 458.73M | Total Assets |
| 978.03M | 575.76M | 603.13M | 605.90M | 487.18M | Total Debt |
| 87.76M | 84.67M | 17.34M | 17.96M | 17.99M | Net Debt |
| -32.49M | -25.29M | -51.06M | -30.01M | -13.01M | Total Liabilities |
| 142.42M | 180.79M | 112.98M | 146.27M | 203.29M | Stockholders Equity |
| 835.62M | 394.97M | 490.15M | 459.64M | 283.89M |
| Cash Flow | Free Cash Flow | |||
| -207.34M | -137.31M | -155.92M | -130.54M | 79.03M | Operating Cash Flow |
| -194.50M | -102.83M | -153.09M | -128.95M | 88.13M | Investing Cash Flow |
| -404.08M | 139.89M | 20.52M | -99.83M | -422.59M | Financing Cash Flow |
| 608.85M | 4.19M | 153.00M | 250.28M | 289.26M |
Kymera Therapeutics Technical Analysis
Negative
35.10
Price Trends
37.62
Negative
41.57
Negative
41.48
Negative
Market Momentum
-1.36
Negative
44.68
Neutral
77.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Negative. The current price of 35.1 is above the 20-day moving average (MA) of 34.12, below the 50-day MA of 37.62, and below the 200-day MA of 41.48, indicating a bearish trend. The MACD of -1.36 indicates Negative momentum. The RSI at 44.68 is Neutral, neither overbought nor oversold. The STOCH value of 77.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KYMR.
Kymera Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $3.55B | ― | -214.50% | ― | 29.01% | 23.93% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
48 Neutral | $2.16B | ― | -36.38% | ― | -40.11% | -17.79% | |
46 Neutral | $3.63B | ― | -19.20% | ― | -89.95% | -123.71% | |
44 Neutral | $570.81M | ― | -35.41% | ― | -39.92% | 7.38% | |
42 Neutral | $38.57M | ― | -270.20% | ― | 144.50% | -141.91% | |
39 Underperform | $962.71M | ― | -54.00% | ― | 59.55% | 3.09% |
* Healthcare Sector Average
Performance Comparison
KYMR
Kymera Therapeutics
33.45
-6.06
-15.34%
BLUE
Bluebird Bio
3.73
-22.87
-85.98%
RARE
Ultragenyx Pharmaceutical
39.25
-7.40
-15.86%
NTLA
Intellia Therapeutics
9.22
-18.30
-66.50%
CRSP
Crispr Therapeutics AG
41.99
-30.02
-41.69%
ARVN
Arvinas Holding Company
8.55
-36.17
-80.88%
Kymera Therapeutics Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -0.74% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant clinical progress and strategic initiatives, such as the advancement of STAT6 and TYK2 programs and the expansion of collaboration with Sanofi, which supports a positive outlook. However, increased operational costs and limited revenue diversification present challenges.Highlights
Clinical Progress in STAT6 and TYK2 Programs
Kymera completed IND-enabling studies for KT-621, initiated a Phase I study, and advanced KT-295 with plans for clinical data readouts in 2025. This positions the company as a leader in STAT6 targeted therapy development.
Sanofi Collaboration Expansion
Sanofi expanded the Phase IIb studies in hidradenitis suppurativa and atopic dermatitis to accelerate development timelines towards pivotal trials, indicating strong progress and partnership value.
Strong Financial Position
Kymera ended 2024 with a cash balance of $851 million, providing runway into mid-2027 to support multiple data readouts, including significant Phase II trials.
Introduction of New Immunology Target
Kymera plans to unveil a new immunology program targeting an undrugged transcription factor, expected to be a first-in-class agent for autoimmune diseases.
Lowlights
Increased R&D and G&A Expenses
R&D expenses increased by 23% sequentially from the third quarter to $71.8 million, and G&A expenses rose by 13% to $16.3 million, reflecting higher operational costs.
Limited Revenue from Collaborations
The fourth-quarter revenue was $7.4 million, solely from the Sanofi collaboration, indicating limited diversification in revenue streams.
Company Guidance
During the Kymera Therapeutics Fourth Quarter 2024 Results Call, the company outlined several key performance metrics and plans for the upcoming year. The Chief Executive Officer, Nello Mainolfi, highlighted the completion of IND-enabling studies for STAT6 (KT-621), the initiation of a Phase I study, and plans to complete the final MAD cohorts. The company also named KT-295 as a development candidate for TYK2, with IND-enabling studies underway. In collaboration with Sanofi, Kymera is progressing two Phase IIb studies for IRAK4 in hidradenitis suppurativa and atopic dermatitis, which have been expanded to accelerate timelines towards pivotal trials. Financially, the company reported $7.4 million in revenue for Q4 2024, all from its Sanofi collaboration, and ended the year with $851 million in cash, providing a runway into mid-2027. For 2025, Kymera plans to report Phase I data for KT-621 in June and initiate two Phase 2b studies, with a goal of delivering at least one new IND per year.Kymera Therapeutics Corporate Events
Executive/Board Changes
Kymera Therapeutics Grants Performance Stock Units to Executives
Neutral
Mar 3, 2025
On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of performance stock units (PSUs) to key employees, including executives, under the company’s 2020 Stock Option and Incentive Plan. These PSUs will vest in three installments based on achieving specific clinical milestones, potentially impacting employee incentives and aligning them with the company’s clinical development goals.
Product-Related AnnouncementsBusiness Operations and Strategy
Kymera Therapeutics Unveils 2025 Strategy and Trials
Positive
Jan 14, 2025
On January 14, 2025, Kymera Therapeutics announced its 2025 objectives and strategy, focusing on advancing its immunology programs, particularly the investigational oral degrader KT-621. The company is conducting a Phase 1 trial for KT-621, with plans to move into Phase 1b and 2b trials by late 2025 and early 2026, targeting conditions like atopic dermatitis and asthma. Kymera is also set to introduce a novel oral immunology program in the first half of 2025. The announcements highlight the company’s commitment to expanding its pipeline and leveraging targeted protein degradation to offer biologics-like oral therapies, positioning itself as a leader in the field.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.